Abstract
CARD14-associated papulosquamous eruption (CAPE) was proposed in 2018 to describe the clinical features of psoriasis and pityriasis rubra pilaris with CARD 14 mutations. We report a 5-month-old female infant who developed CAPE-associated erythroderma. Although she did not respond to conventional therapies, she responded well to ustekinumab treatment at the age of 4 years.
Keywords:
genetic diseases/genodermatoses; inflammatory disorders; psoriasis.
© 2022 Wiley Periodicals LLC.
MeSH terms
-
CARD Signaling Adaptor Proteins / genetics
-
Child, Preschool
-
Dermatitis, Exfoliative* / diagnosis
-
Dermatitis, Exfoliative* / drug therapy
-
Exanthema* / drug therapy
-
Female
-
Guanylate Cyclase / genetics
-
Guanylate Cyclase / therapeutic use
-
Humans
-
Infant
-
Membrane Proteins / therapeutic use
-
Pityriasis Rubra Pilaris* / diagnosis
-
Pityriasis Rubra Pilaris* / drug therapy
-
Psoriasis* / diagnosis
-
Psoriasis* / drug therapy
-
Psoriasis* / genetics
-
Ustekinumab / therapeutic use
Substances
-
CARD Signaling Adaptor Proteins
-
CARD14 protein, human
-
Guanylate Cyclase
-
Membrane Proteins
-
Ustekinumab